PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 2070480
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 2070480
CRISPR Therapeutics Market Size, Share, Growth, Global Industry Analysis, Regional Insights and Forecast to 2026-2034
Growth Factors of CRISPR therapeutics Market
The global CRISPR therapeutics market size was valued at USD 116.0 million in 2025 and is projected to grow from USD 240.0 million in 2026 to USD 6,300.0 million by 2034, exhibiting a remarkable CAGR of 50.45% during the forecast period (2026-2034). North America dominated the market with a 71.29% market share in 2025, supported by early commercialization of CRISPR-based therapies, strong regulatory backing, and advanced gene therapy infrastructure.
CRISPR therapeutics represent a revolutionary approach to disease treatment by directly editing genetic material at the DNA level. Unlike conventional therapies that primarily manage symptoms, CRISPR-based treatments target the root cause of genetic disorders. The market is witnessing rapid expansion due to the commercial success of CASGEVY, the first approved CRISPR gene-editing therapy, alongside growing investments in gene-editing research, improved delivery technologies, and expanding clinical pipelines targeting rare and chronic diseases.
Market Trends
Advancements in Gene-Editing Technologies Driving Innovation
The market is witnessing rapid technological advancements in gene-editing platforms, including base editing, next-generation CRISPR systems, and improved delivery mechanisms. These innovations are enhancing editing precision while reducing off-target effects, allowing developers to target a broader range of diseases such as liver disorders, cardiovascular conditions, metabolic diseases, and inherited genetic disorders.
In March 2026, Beam Therapeutics reported promising Phase 1/2 clinical data for BEAM-302 targeting alpha-1 antitrypsin deficiency, highlighting the growing potential of advanced CRISPR technologies.
Market Drivers
Rising Clinical Trials for Rare Genetic Diseases
The increasing number of clinical trials targeting rare genetic disorders is a major growth driver. CRISPR therapies offer the potential for one-time curative treatments, making them highly attractive for conditions with limited treatment options.
In September 2025, Intellia Therapeutics completed enrollment in the Phase 3 HAELO study evaluating lonvoguran ziclumeran for hereditary angioedema, demonstrating strong momentum in clinical development.
Expanding Regulatory Support
Regulatory agencies are increasingly supporting innovative gene-editing therapies through expedited pathways and special designations. This support reduces development risks and accelerates commercialization opportunities for CRISPR-based treatments.
Market Restraints
High Treatment Costs
CRISPR therapies involve complex manufacturing processes, personalized cell collection, genetic modification, conditioning regimens, and long-term monitoring. These factors contribute to high treatment costs and create reimbursement challenges, particularly in developing economies.
The need for country-specific reimbursement agreements continues to slow large-scale adoption despite clinical success.
Market Opportunities
Growing Acceptance of One-Time Curative Therapies
Healthcare providers and patients are increasingly embracing curative treatment approaches. Improved delivery systems, broader regulatory support, and ongoing pipeline expansion create significant opportunities for CRISPR developers to enter new disease areas and patient populations.
Market Challenges
Ethical Concerns Surrounding Gene Editing
Ethical debates regarding human genome editing remain a significant challenge. Concerns related to long-term safety, misuse of gene-editing technologies, and potential future germline applications continue to attract regulatory scrutiny and public attention.
Segmentation Analysis
By Product
The CASGEVY segment held the largest market share in 2025 due to its status as the first approved CRISPR/Cas9 gene-editing therapy. Growing reimbursement approvals and treatment center expansion continue to support adoption.
By Indication
The sickle cell disease segment dominated the market in 2025 owing to its large patient population and strong demand for transformative treatment options.
By Age Group
The adult segment accounted for the largest market share in 2025 as most currently approved therapies and clinical programs focus on adult patients.
By End User
The hospitals segment led the market due to the specialized infrastructure required for stem cell collection, gene editing, infusion procedures, and post-treatment monitoring.
Regional Outlook
North America
North America remained the leading regional market with a value of USD 82.7 million in 2025. The region benefits from advanced healthcare infrastructure, strong research capabilities, and early adoption of gene-editing therapies.
U.S. Market
The U.S. CRISPR therapeutics market is projected to reach approximately USD 146.9 million in 2026, accounting for nearly 61.2% of global revenue.
Europe
Europe is projected to grow at a CAGR of 51.75% during the forecast period. Expanding reimbursement agreements and increasing access to CASGEVY are supporting regional growth.
Asia Pacific
Asia Pacific is expected to register the fastest growth rate owing to its large patient population, increasing healthcare investments, and growing interest in advanced gene therapies.
Latin America and Middle East & Africa
These regions are expected to experience notable growth driven by increasing awareness of gene-editing therapies, expanding healthcare access, and government support for innovative treatments.
Competitive Landscape
The CRISPR therapeutics market is highly concentrated, with leading companies focusing on commercial expansion, clinical pipeline advancement, and strategic partnerships.
Key Companies Profiled
- Vertex Pharmaceuticals Incorporated (U.S.)
- Intellia Therapeutics, Inc. (U.S.)
- Beam Therapeutics (U.S.)
- Eli Lilly and Company (Verve Therapeutics, Inc.) (U.S.)
- CRISPR Therapeutics (Switzerland)
- Editas Medicine (U.S.)
Key Industry Developments
- March 2026: Intellia Therapeutics received FDA clearance to continue the Phase 3 MAGNITUDE trial for nexiguran ziclumeran.
- February 2026: Beam Therapeutics expanded its liver-targeted gene-editing portfolio with BEAM-304 for phenylketonuria.
- January 2026: Vertex secured a reimbursement agreement in England for CASGEVY.
- September 2025: CRISPR Therapeutics and Sirius Therapeutics initiated Phase 2 studies for SRSD107 in Europe.
- May 2025: CRISPR Therapeutics entered a strategic collaboration with Sirius Therapeutics to develop novel gene-based medicines.
Conclusion
The CRISPR therapeutics market is entering a transformative growth phase, driven by the commercial success of CASGEVY, rapid advancements in gene-editing technologies, expanding clinical pipelines, and strong regulatory support. The market is expected to grow from USD 116.0 million in 2025 to USD 240.0 million in 2026 and reach USD 6,300.0 million by 2034, reflecting the increasing adoption of one-time curative therapies. While high treatment costs and ethical concerns remain challenges, continued innovation, expanding reimbursement coverage, and growing clinical success are expected to position CRISPR therapeutics as a major pillar of future precision medicine.
Segmentation By Product, Indication, Age Group, End User, and Region
By Product * CASGEVY
- Others
By Indication * Sickle Cell Disease
- Transfusion-Dependent Beta Thalassemia
- Others
By Age Group * Pediatric
- Adult
By End User * Hospitals
- Specialty Treatment Centers
- Others
By Region * North America (By Product, Indication, Age Group, End User, and Country)
- U.S.
- Canada
- Europe (By Product, Indication, Age Group, End User, and Country/Sub-region)
- Germany
- U.K.
- France
- Spain
- Italy
- Rest of Europe
- Asia Pacific (By Product, Indication, Age Group, End User, and Country/Sub-region)
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America (By Product, Indication, Age Group, End User, and Country/Sub-region)
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa (By Product, Indication, Age Group, End User, and Country/Sub-region)
- GCC
- South Africa
- Rest of Middle East & Africa
Table of Content
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
4. Key Insights
- 4.1. Pipeline Analysis, By Key Players
- 4.2. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
- 4.3. New Product Launches, By Key Players
- 4.4. Regulatory Scenario, By Key Countries/Regions
- 4.5. Technological Advancements in CRISPR Technologies
5. Global CRISPR Therapeutics Market Analysis, Insights and Forecast, 2021-2034
- 5.1. Market Analysis, Insights and Forecast - By Product
- 5.1.1. CASGEVY
- 5.1.2. Others
- 5.2. Market Analysis, Insights and Forecast - By Indication
- 5.2.1. Sickle Cell Disease
- 5.2.2. Transfusion-Dependent Beta Thalassemia
- 5.2.3. Others
- 5.3. Market Analysis, Insights and Forecast - By Age Group
- 5.3.1. Pediatric
- 5.3.2. Adult
- 5.4. Market Analysis, Insights and Forecast - By End User
- 5.4.1. Hospitals
- 5.4.2. Specialty Treatment Centers
- 5.4.3. Others
- 5.5. Market Analysis, Insights and Forecast - Region
- 5.5.1. North America
- 5.5.2. Europe
- 5.5.3. Asia Pacific
- 5.5.4. Latin America
- 5.5.5. Middle East & Africa
6. North America CRISPR Therapeutics Market Analysis, Insights and Forecast, 2021-2034
- 6.1. Market Analysis, Insights and Forecast - By Product
- 6.1.1. CASGEVY
- 6.1.2. Others
- 6.2. Market Analysis, Insights and Forecast - By Indication
- 6.2.1. Sickle Cell Disease
- 6.2.2. Transfusion-Dependent Beta Thalassemia
- 6.2.3. Others
- 6.3. Market Analysis, Insights and Forecast - By Age Group
- 6.3.1. Pediatric
- 6.3.2. Adult
- 6.4. Market Analysis, Insights and Forecast - By End User
- 6.4.1. Hospitals
- 6.4.2. Specialty Treatment Centers
- 6.4.3. Others
- 6.5. Market Analysis, Insights and Forecast - By Country
- 6.5.1. U.S.
- 6.5.2. Canada
7. Europe CRISPR Therapeutics Market Analysis, Insights and Forecast, 2021-2034
- 7.1. Market Analysis, Insights and Forecast - By Product
- 7.1.1. CASGEVY
- 7.1.2. Others
- 7.2. Market Analysis, Insights and Forecast - By Indication
- 7.2.1. Sickle Cell Disease
- 7.2.2. Transfusion-Dependent Beta Thalassemia
- 7.2.3. Others
- 7.3. Market Analysis, Insights and Forecast - By Age Group
- 7.3.1. Pediatric
- 7.3.2. Adult
- 7.4. Market Analysis, Insights and Forecast - By End User
- 7.4.1. Hospitals
- 7.4.2. Specialty Treatment Centers
- 7.4.3. Others
- 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 7.5.1. U.K.
- 7.5.2. Germany
- 7.5.3. France
- 7.5.4. Italy
- 7.5.5. Spain
- 7.5.6. Rest of Europe
8. Asia Pacific CRISPR Therapeutics Market Analysis, Insights and Forecast, 2021-2034
- 8.1. Market Analysis, Insights and Forecast - By Product
- 8.1.1. CASGEVY
- 8.1.2. Others
- 8.2. Market Analysis, Insights and Forecast - By Indication
- 8.2.1. Sickle Cell Disease
- 8.2.2. Transfusion-Dependent Beta Thalassemia
- 8.2.3. Others
- 8.3. Market Analysis, Insights and Forecast - By Age Group
- 8.3.1. Pediatric
- 8.3.2. Adult
- 8.4. Market Analysis, Insights and Forecast - By End User
- 8.4.1. Hospitals
- 8.4.2. Specialty Treatment Centers
- 8.4.3. Others
- 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 8.5.1. China
- 8.5.2. Japan
- 8.5.3. India
- 8.5.4. Australia
- 8.5.5. South Korea
- 8.5.6. Rest of Asia Pacific
9. Latin America CRISPR Therapeutics Market Analysis, Insights and Forecast, 2021-2034
- 9.1. Market Analysis, Insights and Forecast - By Product
- 9.1.1. CASGEVY
- 9.1.2. Others
- 9.2. Market Analysis, Insights and Forecast - By Indication
- 9.2.1. Sickle Cell Disease
- 9.2.2. Transfusion-Dependent Beta Thalassemia
- 9.2.3. Others
- 9.3. Market Analysis, Insights and Forecast - By Age Group
- 9.3.1. Pediatric
- 9.3.2. Adult
- 9.4. Market Analysis, Insights and Forecast - By End User
- 9.4.1. Hospitals
- 9.4.2. Specialty Treatment Centers
- 9.4.3. Others
- 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 9.5.1. Brazil
- 9.5.2. Mexico
- 9.5.3. Rest of Latin America
10. Middle East & Africa CRISPR Therapeutics Market Analysis, Insights and Forecast, 2021-2034
- 10.1. Market Analysis, Insights and Forecast - By Product
- 10.1.1. CASGEVY
- 10.1.2. Others
- 10.2. Market Analysis, Insights and Forecast - By Indication
- 10.2.1. Sickle Cell Disease
- 10.2.2. Transfusion-Dependent Beta Thalassemia
- 10.2.3. Others
- 10.3. Market Analysis, Insights and Forecast - By Age Group
- 10.3.1. Pediatric
- 10.3.2. Adult
- 10.4. Market Analysis, Insights and Forecast - By End User
- 10.4.1. Hospitals
- 10.4.2. Specialty Treatment Centers
- 10.4.3. Others
- 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 10.5.1. GCC
- 10.5.2. South Africa
- 10.5.3. Rest of Middle East & Africa
11. Competitive Analysis
- 11.1. Global Market Share Analysis (2025)
- 11.2. Company Profiles
- 11.2.1. Vertex Pharmaceuticals Incorporated
- 11.2.2. Intellia Therapeutics, Inc.
- 11.2.3. Beam Therapeutics.
- 11.2.4. Eli Lilly and Company (Verve Therapeutics, Inc.)
- 11.2.5. CRISPR Therapeutics
- 11.2.6. Editas Medicine
List of Tables
- Figure 1: Global CRISPR Therapeutics Market Revenue Breakdown (USD million, %) By Region, 2025 & 2034
- Figure 2: Global CRISPR Therapeutics Market Value Share (%), By Product, 2025 & 2034
- Figure 3: Global CRISPR Therapeutics Market Value Share (%), By Indication, 2025 & 2034
- Figure 4: Global CRISPR Therapeutics Market Value Share (%), By Age Group, 2025 & 2034
- Figure 5: Global CRISPR Therapeutics Market Value Share (%), By End User, 2025 & 2034
- Figure 6: Global CRISPR Therapeutics Market Value Share (%), By Region, 2025 & 2034
- Figure 7: North America CRISPR Therapeutics Market Value (USD million), By Product, 2025 & 2034
- Figure 8: North America CRISPR Therapeutics Market Value Share (%), By Product, 2025
- Figure 9: North America CRISPR Therapeutics Market Value (USD million), By Indication, 2025 & 2034
- Figure 10: North America CRISPR Therapeutics Market Value Share (%), By Indication, 2025
- Figure 11: North America CRISPR Therapeutics Market Value (USD million), By Age Group, 2025 & 2034
- Figure 12: North America CRISPR Therapeutics Market Value Share (%), By Age Group, 2025
- Figure 13: North America CRISPR Therapeutics Market Value (USD million), By End User, 2025 & 2034
- Figure 14: North America CRISPR Therapeutics Market Value Share (%), By End User, 2025
- Figure 15: North America CRISPR Therapeutics Market Value (USD million), by Country, 2025 & 2034
- Figure 16: North America CRISPR Therapeutics Market Value Share (%), by Country, 2025
- Figure 17: Europe CRISPR Therapeutics Market Value (USD million), By Product, 2025 & 2034
- Figure 18: Europe CRISPR Therapeutics Market Value Share (%), By Product, 2025
- Figure 19: Europe CRISPR Therapeutics Market Value (USD million), By Indication, 2025 & 2034
- Figure 20: Europe CRISPR Therapeutics Market Value Share (%), By Indication, 2025
- Figure 21: Europe CRISPR Therapeutics Market Value (USD million), By Age Group, 2025 & 2034
- Figure 22: Europe CRISPR Therapeutics Market Value Share (%), By Age Group, 2025
- Figure 23: Europe CRISPR Therapeutics Market Value (USD million), By End User, 2025 & 2034
- Figure 24: Europe CRISPR Therapeutics Market Value Share (%), By End User, 2025
- Figure 25: Europe CRISPR Therapeutics Market Value (USD million), by Country/ Sub-region, 2025 & 2034
- Figure 26: Europe CRISPR Therapeutics Market Value Share (%), by Country/ Sub-region, 2025
- Figure 27: Asia Pacific CRISPR Therapeutics Market Value (USD million), By Product, 2025 & 2034
- Figure 28: Asia Pacific CRISPR Therapeutics Market Value Share (%), By Product, 2025
- Figure 29: Asia Pacific CRISPR Therapeutics Market Value (USD million), By Indication, 2025 & 2034
- Figure 30: Asia Pacific CRISPR Therapeutics Market Value Share (%), By Indication, 2025
- Figure 31: Asia Pacific CRISPR Therapeutics Market Value (USD million), By Age Group, 2025 & 2034
- Figure 32: Asia Pacific CRISPR Therapeutics Market Value Share (%), By Age Group, 2025
- Figure 33: Asia Pacific CRISPR Therapeutics Market Value (USD million), By End User, 2025 & 2034
- Figure 34: Asia Pacific CRISPR Therapeutics Market Value Share (%), By End User, 2025
- Figure 35: Asia Pacific CRISPR Therapeutics Market Value (USD million), by Country/ Sub-region, 2025 & 2034
- Figure 36: Asia Pacific CRISPR Therapeutics Market Value Share (%), by Country/ Sub-region, 2025
- Figure 37: Latin America CRISPR Therapeutics Market Value (USD million), By Product, 2025 & 2034
- Figure 38: Latin America CRISPR Therapeutics Market Value Share (%), By Product, 2025
- Figure 39: Latin America CRISPR Therapeutics Market Value (USD million), By Indication, 2025 & 2034
- Figure 40: Latin America CRISPR Therapeutics Market Value Share (%), By Indication, 2025
- Figure 41: Latin America CRISPR Therapeutics Market Value (USD million), By Age Group, 2025 & 2034
- Figure 42: Latin America CRISPR Therapeutics Market Value Share (%), By Age Group, 2025
- Figure 43: Latin America CRISPR Therapeutics Market Value (USD million), By End User, 2025 & 2034
- Figure 44: Latin America CRISPR Therapeutics Market Value Share (%), By End User, 2025
- Figure 45: Latin America CRISPR Therapeutics Market Value (USD million), by Country/ Sub-region, 2025 & 2034
- Figure 46: Latin America CRISPR Therapeutics Market Value Share (%), by Country/ Sub-region, 2025
- Figure 47: Middle East & Africa CRISPR Therapeutics Market Value (USD million), By Product, 2025 & 2034
- Figure 48: Middle East & Africa CRISPR Therapeutics Market Value Share (%), By Product, 2025
- Figure 49: Middle East & Africa CRISPR Therapeutics Market Value (USD million), By Indication, 2025 & 2034
- Figure 50: Middle East & Africa CRISPR Therapeutics Market Value Share (%), By Indication, 2025
- Figure 51: Middle East & Africa CRISPR Therapeutics Market Value (USD million), By Age Group, 2025 & 2034
- Figure 52: Middle East & Africa CRISPR Therapeutics Market Value Share (%), By Age Group, 2025
- Figure 53: Middle East & Africa CRISPR Therapeutics Market Value (USD million), By End User, 2025 & 2034
- Figure 54: Middle East & Africa CRISPR Therapeutics Market Value Share (%), By End User, 2025
- Figure 55: Middle East & Africa CRISPR Therapeutics Market Value (USD million), by Country/ Sub-region, 2025 & 2034
- Figure 56: Middle East & Africa CRISPR Therapeutics Market Value Share (%), by Country/ Sub-region, 2025
- Figure 57: Global CRISPR Therapeutics Market Share (%), by Company, 2025
